Octávio Barbosa Neto1,2, Gustavo Ribeiro da Mota3, Carla Cristina De Sordi4, Elisabete Aparecida M R Resende4, Luiz Antônio P R Resende5, Marco Antônio Vieira da Silva5, Moacir Marocolo6, Rafael Silva Côrtes7, Lucas Felipe de Oliveira7, Valdo José Dias da Silva7. 1. Human Performance and Sport Research Group, Postgraduate Program in Physical Education, Federal University of Triângulo Mineiro, Av. Tutunas, 490, Uberaba, MG, 38061-500, Brazil. octavio.neto@uftm.edu.br. 2. Department of Physiology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil. octavio.neto@uftm.edu.br. 3. Human Performance and Sport Research Group, Postgraduate Program in Physical Education, Federal University of Triângulo Mineiro, Av. Tutunas, 490, Uberaba, MG, 38061-500, Brazil. 4. Department of Endocrinology and Metabolism, School of Medicine at the Federal University of Triângulo Mineiro, Uberaba, MG, Brazil. 5. Department of Cardiology, School of Medicine at the Federal University of Triângulo Mineiro, Uberaba, MG, Brazil. 6. Department of Physiology, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil. 7. Department of Physiology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil.
Abstract
OBJECTIVE: The aims of this study were to examine the hypothesis that users of anabolic androgenic steroids (AAS) would have cardiac autonomic disorders and that there is a correlation between sympathetic modulation, high blood pressure (BP) and alterations to cardiac dimensions. METHODS: Forty-five male subjects were enrolled in the study. They were categorized into three groups comprising bodybuilders actively using AAS (AAS users; n = 15), bodybuilders who had never used AAS (nonusers; n = 15) and age-paired healthy sedentary controls (n = 15). Hemodynamic parameters, linear and nonlinear analyses of heart rate variability and electrocardiography and echocardiography analyses were performed at rest. RESULTS: Bodybuilders in the AAS group had a higher mean BP than those in the ASS nonuser group (p < 0.05) and the sedentary controls (p < 0.001). Cardiac sympathetic modulation was higher in AAS users than in AAS nonusers (p < 0.05) and the sedentary controls (p < 0.001), and parasympathetic modulation was lower in AAS users than in nonusers and the sedentary controls (p < 0.05). Shannon entropy was lower in AAS users than in the sedentary (p < 0.05) controls, and the corrected QT interval and QT dispersion were higher in AAS users than in the sedentary controls (p < 0.05). The interventricular septal thickness, left ventricle posterior wall thickness and relative diastolic wall thickness were higher in AAS users than in AAS nonusers and the sedentary controls (p < 0.001). AAS users showed a positive correlation between increased sympathetic modulation and high BP (r = 0.48, p < 0.005), as well as sympathetic modulation and cardiac hypertrophy (r = 0.66, p < 0.001). CONCLUSION: There was a marked cardiac autonomic alteration in AAS users, with a shift toward sympathetic modulation predominance and vagal attenuation. The high BP observed in our group of bodybuilders using AAS was associated with increased sympathetic modulation, and this increased sympathetic modulation was associated with structural alterations in the heart. This association may constitute an important mechanism linking AAS abuse to increased cardiovascular risk.
OBJECTIVE: The aims of this study were to examine the hypothesis that users of anabolic androgenic steroids (AAS) would have cardiac autonomic disorders and that there is a correlation between sympathetic modulation, high blood pressure (BP) and alterations to cardiac dimensions. METHODS: Forty-five male subjects were enrolled in the study. They were categorized into three groups comprising bodybuilders actively using AAS (AAS users; n = 15), bodybuilders who had never used AAS (nonusers; n = 15) and age-paired healthy sedentary controls (n = 15). Hemodynamic parameters, linear and nonlinear analyses of heart rate variability and electrocardiography and echocardiography analyses were performed at rest. RESULTS: Bodybuilders in the AAS group had a higher mean BP than those in the ASS nonuser group (p < 0.05) and the sedentary controls (p < 0.001). Cardiac sympathetic modulation was higher in AAS users than in AAS nonusers (p < 0.05) and the sedentary controls (p < 0.001), and parasympathetic modulation was lower in AAS users than in nonusers and the sedentary controls (p < 0.05). Shannon entropy was lower in AAS users than in the sedentary (p < 0.05) controls, and the corrected QT interval and QT dispersion were higher in AAS users than in the sedentary controls (p < 0.05). The interventricular septal thickness, left ventricle posterior wall thickness and relative diastolic wall thickness were higher in AAS users than in AAS nonusers and the sedentary controls (p < 0.001). AAS users showed a positive correlation between increased sympathetic modulation and high BP (r = 0.48, p < 0.005), as well as sympathetic modulation and cardiac hypertrophy (r = 0.66, p < 0.001). CONCLUSION: There was a marked cardiac autonomic alteration in AAS users, with a shift toward sympathetic modulation predominance and vagal attenuation. The high BP observed in our group of bodybuilders using AAS was associated with increased sympathetic modulation, and this increased sympathetic modulation was associated with structural alterations in the heart. This association may constitute an important mechanism linking AAS abuse to increased cardiovascular risk.
Authors: E Pruvot; G Thonet; J M Vesin; G van-Melle; K Seidl; H Schmidinger; J Brachmann; W Jung; E Hoffmann; R Tavernier; M Block; A Podczeck; M Fromer Journal: Circulation Date: 2000-05-23 Impact factor: 29.690
Authors: Mateus C Laterza; Luciana D N J de Matos; Ivani C Trombetta; Ana M W Braga; Fabiana Roveda; Maria J N N Alves; Eduardo M Krieger; Carlos E Negrão; Maria U P B Rondon Journal: Hypertension Date: 2007-04-16 Impact factor: 10.190
Authors: J M Zmuda; M C Fahrenbach; B T Younkin; L L Bausserman; R B Terry; D H Catlin; P D Thompson Journal: Metabolism Date: 1993-04 Impact factor: 8.694
Authors: V Shusterman; B Aysin; V Gottipaty; R Weiss; S Brode; D Schwartzman; K P Anderson Journal: J Am Coll Cardiol Date: 1998-12 Impact factor: 24.094
Authors: Xiao-Ke Liu; Alexander Katchman; Bernard H Whitfield; Grace Wan; Einsley M Janowski; Raymond L Woosley; Steven N Ebert Journal: Cardiovasc Res Date: 2003-01 Impact factor: 10.787
Authors: Evangelia Joseph Kouidi; Antonia Kaltsatou; Maria Apostolos Anifanti; Asterios Pantazis Deligiannis Journal: Int J Environ Res Public Health Date: 2021-06-29 Impact factor: 3.390
Authors: Giovanni Corona; Giulia Rastrelli; Sara Marchiani; Sandra Filippi; Annamaria Morelli; Erica Sarchielli; Alessandra Sforza; Linda Vignozzi; Mario Maggi Journal: World J Mens Health Date: 2021-06-01 Impact factor: 5.400